Radiopharm Theranostics (RADX) Total Liabilities (2024 - 2025)
Radiopharm Theranostics (RADX) has disclosed Total Liabilities for 2 consecutive years, with $43.6 million as the latest value for Q2 2025.
- Quarterly Total Liabilities fell 2.4% to $43.6 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $43.6 million through Jun 2025, down 2.4% year-over-year, with the annual reading at $43.6 million for FY2025, 2.4% down from the prior year.
- Total Liabilities for Q2 2025 was $43.6 million at Radiopharm Theranostics, down from $44.7 million in the prior quarter.
- The five-year high for Total Liabilities was $44.7 million in Q2 2024, with the low at $43.6 million in Q2 2025.